GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Danuglipron

Company
Pfizer
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT03309241

    First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

    Not yet reported Pfizer 25 participants Est. completion 2018-03-22 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT03492697

    A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

    Not yet reported Pfizer 12 participants Est. completion 2018-07-18 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT03538743

    4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

    Not yet reported Pfizer 98 participants Est. completion 2019-06-10 4 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03985293

    A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

    Not yet reported Pfizer 412 participants Est. completion 2021-07-07 83 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04495140

    Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

    Not yet reported Pfizer 6 participants Est. completion 2020-10-15 2 sites
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Completed NCT NCT04552470

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus

    Not yet reported Pfizer 37 participants Est. completion 2021-03-25 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04604496

    STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

    Not yet reported Pfizer 24 participants Est. completion 2022-01-10 2 sites
    Other conditions: Hepatic Impairment, Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04616027

    STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

    Not yet reported Pfizer 42 participants Est. completion 2022-02-18 3 sites
    Type 2 diabetes Other conditions: Renal Impairment, Healthy
    View official trial listing →
  • Completed NCT NCT04616339

    STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

    Not yet reported Pfizer 31 participants Est. completion 2021-07-19 1 site Stand-alone
    Other conditions: Overweight and/or Obesity
    View official trial listing →
  • Completed NCT NCT04617275

    A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

    Not yet reported Pfizer 151 participants Est. completion 2021-11-17 38 sites
    Other conditions: Diabetes, Obesity
    View official trial listing →
  • Completed NCT NCT04621227

    Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

    Not yet reported Pfizer 16 participants Est. completion 2021-05-13 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT04707313

    A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

    Not yet reported Pfizer 628 participants Est. completion 2023-10-11 41 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT04839393

    A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

    Not yet reported Pfizer 27 participants Est. completion 2021-11-08 1 site
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Completed NCT NCT04889157

    A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

    Not yet reported Pfizer 20 participants Est. completion 2022-02-17 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05093205

    STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

    Not yet reported Pfizer 35 participants Est. completion 2022-07-06 1 site
    Other conditions: Healthy Adults
    View official trial listing →
  • Completed NCT NCT06153758

    Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

    Not yet reported Pfizer 33 participants Est. completion 2024-09-30 1 site Stand-alone
    Other conditions: Healthy Participants, Healthy Subjects
    View official trial listing →
  • Completed NCT NCT06541678

    A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

    Not yet reported Pfizer 16 participants Est. completion 2025-03-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06567327

    A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

    Not yet reported Pfizer 82 participants Est. completion 2025-04-14 3 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06568731

    A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

    Not yet reported Pfizer 23 participants Est. completion 2024-12-18 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Terminated NCT NCT06910839

    Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

    Not yet reported Pfizer 21 participants Est. completion 2025-05-20 1 site
    Other conditions: Overweight, Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.